Press Releases April 14, 2026 10:54 AM

Results of the Stellantis 2026 Annual General Meeting

Stellantis Shareholders Approve All AGM Resolutions Including Director Appointments and Committee Establishments

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
STLA

Stellantis N.V. announced that its 2026 Annual General Meeting resulted in a large majority approval of all submitted resolutions. Key director roles were reaffirmed with the re-election of John Elkann as executive director and the appointment of Juergen Esser as a new non-executive director. The Board formed Audit, Remuneration, and ESG Committees, with corresponding chairs named. The advisory vote on the Remuneration Report received strong shareholder support at 93.17%.

Results of the Stellantis 2026 Annual General Meeting
STLA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All AGM resolutions, including director re-elections and appointments, received large majority shareholder approval.
  • The Board of Directors established key committees: Audit, Remuneration, and ESG, assigning leadership roles.
  • The advisory vote on the Remuneration Report delivered high shareholder support at 93.17%.
  • Sectors impacted include the automotive industry, corporate governance, and ESG (Environmental, Social, and Governance) frameworks.

Results of the Stellantis 2026 Annual General Meeting

AMSTERDAM, April 14, 2026 – Stellantis N.V. (“Stellantis”) today announced that shareholders approved by a large majority all resolutions submitted at the Annual General Meeting (AGM), held in person and webcast live on the Stellantis website.

The AGM re-elected John Elkann as an executive director and Robert Peugeot and Henri de Castries as non-executive directors, and appointed Juergen Esser as an additional non-executive director. All directors will serve a two-year term.

In addition, the Board of Directors re-appointed John Elkann as Chairman, Robert Peugeot as Vice Chairman, and Henri de Castries as Senior Independent Director, acting as Chair of the Board (or “voorzitter”).

The Board established the following committees:

  • Audit Committee: Ms. Ann Godbehere (Chairperson), Mr. Henri de Castries, Mr. Juergen Esser, and Ms. Alice Schroeder;
  • Remuneration Committee: Ms. Fiona Cicconi (Chairperson), Mr. Henri de Castries, Mr. Robert Peugeot, Mr. Daniel Ramot, and Mr. Benoît Ribadeau-Dumas;
  • ESG Committee: Mr. Henri de Castries (Chairperson), Ms. Fiona Cicconi, Mr. Nicolas Dufourcq, Ms. Claudia Parzani, and Mr. Benoît Ribadeau-Dumas.

The Company also noted the feedback resulting from the advisory vote on the Remuneration Report, in accordance with Dutch AGM regulations, which received 93.17% support.

Details of the resolutions submitted to the AGM are available on the Company’s corporate website (www.stellantis.com).

# # #

About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com.

 

 

 

@Stellantis 

Stellantis 

Stellantis 

Stellantis 

For more information, contact:

 

[email protected]

 

Attachment

  • EN-20260414-Stellantis-AGM-Result

Risks

  • Potential uncertainties around future strategic decisions despite current director appointments.
  • Risks related to evolving regulatory and shareholder expectations in corporate governance and ESG policies.
  • Market and economic factors that could impact the automotive sector and Stellantis's operational performance.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026